Owlet (OWLT) Q2 2025: DreamSock Drives 26% Growth, Tariff Headwinds Temper Margin Outlook

August 7, 2025 | By EarningsIQ Research

Owlet’s Q2 delivered record first-half revenue, propelled by DreamSock adoption and subscription momentum, but rising Asian tariffs and a CEO transition create new cross-currents for the back half. The company’s path to pediatric health platform scale remains on track, though cost structure and hospital channel execution are key watchpoints for investors as Owlet raises full-year guidance.

Summary

• DreamSock Adoption Surges: Domestic and international sell-through growth signals sustained consumer traction and category leadership.
• Tariff Pressure Mounts: Steep Vietnam and Thailand tariff hikes will compress margins despite operating leverage gains.
• Leadership Transition Watch: CEO handoff and new strategic priorities will shape execution in healthcare and platform expansion.

Performance Analysis

Owlet posted its largest first-half revenue in company history, with Q2 sales up 26% year over year to $26.1 million, marking a fifth straight quarter of adjusted EBITDA profitability. Gross margins expanded for the ninth consecutive quarter, reaching 51.3%, but the company faces a step-down in the second half as tariffs on imports from Vietnam and Thailand escalate from 10% to 19%-20%. CFO Amanda Tweed Crawford confirmed a $500,000 Q2 tariff hit, with a projected 5% gross margin impact in Q4, and guided for full-year margins in the 46%-50% range—flat to slightly down from prior expectations despite raised revenue targets.

Operating expenses rose to $15.3 million but improved as a percentage of revenue, reflecting scaling leverage as the company grows. Net loss ballooned on a non-cash warrant revaluation, but underlying operating loss and adjusted EBITDA both improved. Cash balance increased to $21.8 million, aided by a line of credit draw. Notably, Owlet executed a major warrant exchange, eliminating over 90% of Series A and all Series B warrants, reducing future dilution risk and simplifying the capital structure.

• DreamSock Momentum: Domestic sell-through up 37% YoY, with registry additions up 54% and Prime Day sales up 72% YoY.
• International Rebound Pending: Q2 international revenue dropped due to order timing, but sell-through rose 33% YoY, with France and Germany up triple digits.
• Subscription Scale: Owlet 360 surpassed 66,000 paying subscribers, driving recurring revenue and higher attach and retention rates.

Owlet’s business model—selling FDA-cleared pediatric monitors and layering on subscription services—continues to deliver top-line growth and improving operating leverage, but the cost structure is increasingly exposed to global trade policy and supply chain complexity.

Executive Commentary

Strategic Positioning

1. DreamSock and Category Leadership

DreamSock, Owlet’s flagship smart baby monitor, continues to anchor growth with domestic sell-through up 37% and registry additions up 54% YoY. The device remains the only FDA-cleared health monitor in the US, reinforcing brand leadership and pricing power. Prime Day performance and industry awards underscore Owlet’s innovation and brand equity in the baby safety category.

2. Subscription Platform Expansion

Owlet 360, the company’s subscription service, has scaled to over 66,000 paying subscribers within six months of launch. The platform is driving higher attach rates and retention, with new features like sleep position tracking and planned AI-driven insights. Subscription revenue is emerging as a stabilizing, recurring stream, supporting Owlet’s pivot from device sales to a pediatric health platform business model.

3. Healthcare Channel and Data Integration

Owlet Connect, the new enterprise data integration platform, is a strategic bet to unlock the insurance-reimbursed monitor market by enabling real-time data sharing between families and hospitals. Early adoption with Children’s Hospital of the King’s Daughters is a milestone, but revenue remains negligible as hospital onboarding and integration cycles remain slow and complex. Medicaid adoption is expanding, but meaningful healthcare revenue is likely a 2026 story.

4. Tariff and Supply Chain Adaptation

Rising tariffs on Asian imports threaten gross margin stability, prompting Owlet to explore new manufacturing locations and diversify sourcing. The company is actively evaluating alternatives to mitigate tariff impacts as it bumps up against capacity constraints. Cost control and supply chain agility will be critical to sustaining margin expansion as volume grows.

5. Leadership Transition and Strategic Focus

CEO succession from founder Kurt Workman to Jonathan Harris marks a pivotal moment for execution risk and strategic direction. Harris, credited with driving global go-to-market and subscription launch, inherits a business with momentum but faces the challenge of scaling healthcare and navigating cost headwinds. The founder’s move to executive chairman signals continued focus on access, insurance coverage, and clinical evidence-building.

Key Considerations

Owlet’s Q2 illustrates both the power of its consumer franchise and the complexity of scaling into healthcare and platform economics. Investors should weigh the durability of device demand against the emerging risk factors in cost structure and execution.

Key Considerations:

• Subscription Economics: Subscription attach and retention rates are strengthening, but pricing sensitivity and ultimate ARPU remain to be proven at scale.
• Healthcare Channel Ramp: Hospital adoption is slow and integration-intensive, with revenue impact unlikely to materialize near-term.
• Tariff Volatility: Rising Asian tariffs could erode margin gains unless offset by supply chain shifts or price increases.
• Capital Structure Simplification: Warrant exchange eliminates a major overhang, reducing dilution risk and clarifying the equity story.
• Leadership Transition: CEO handoff introduces execution risk but also brings operational focus to platform and healthcare expansion.

Risks

Tariff escalation and supply chain disruption remain the most immediate risks to Owlet’s margin profile. The slow pace of hospital channel monetization could delay healthcare revenue inflection, while device demand could soften if consumer macro weakens. The CEO transition, while planned, adds operational and strategic execution risk at a critical scaling phase. Investors should monitor for further tariff changes, manufacturing adjustments, and evidence of healthcare channel momentum.

Forward Outlook

For Q3 and Q4 2025, Owlet guided to:

• Revenue growth sustained by DreamSock and subscription expansion
• Gross margin decline of approximately 5% in Q4 due to tariff increases

For full-year 2025, management raised guidance:

• Revenue of $97 to $100 million (24%-28% YoY growth)
• Gross margin of 46% to 50% (reflecting new tariffs)
• Full-year adjusted EBITDA profitability now fully expected

Management highlighted several factors that will shape the back half:

• Tariff impact and supply chain adaptation
• Subscription feature launches and telehealth pilot timing
• Hospital integration progress and Medicaid expansion

Takeaways

Owlet’s Q2 underscores its consumer franchise strength and progress toward platform economics, but exposes emerging cost and execution risks as it transitions leadership and scales into healthcare.

• Consumer Demand Resilience: DreamSock and subscription adoption remain robust, positioning Owlet as the clear leader in pediatric health monitoring.
• Margin Compression Watch: Tariff hikes will pressure gross margin in the second half, with mitigation dependent on supply chain moves and pricing discipline.
• Healthcare Channel Patience Required: Hospital and Medicaid channel progress is strategic but slow, with revenue impact likely to lag consumer momentum.

Conclusion

Owlet delivered a record-setting Q2, raising full-year guidance on the back of strong consumer demand and subscription growth. However, investors should closely watch tariff-driven margin pressure, the pace of healthcare channel monetization, and the operational impact of the CEO transition as the company navigates its next phase of platform scale.

Industry Read-Through

Owlet’s results highlight the resilience of premium consumer health devices and the growing appeal of subscription models in pediatric care. The company’s experience with tariff shocks and supply chain constraints is a warning for other device makers reliant on Asian manufacturing, suggesting a renewed urgency for diversification. The slow but steady progress integrating with hospital systems and payers signals that digital health platforms face long sales cycles and complex integration hurdles, with recurring revenue streams from subscriptions offering a more immediate path to profitability than healthcare channel bets. Investors in connected health, baby tech, and consumer IoT should monitor Owlet’s ability to balance innovation, cost control, and channel diversification as industry tailwinds meet geopolitical and execution headwinds.

OWLT Health Care Medical Devices Subscription Tariffs Pediatric Platform